The main methods used to deplete TAMs include the inhibition of CCL2–CCR2 signaling or the activity of the CSF1–CSF1R axis, both of which reduce the numbers of TAMs in tumor sites and improve the efficacy of immunotherapy (Kalbasi et al., 2017; Peranzoni et al., 2018; Wang et al., 2018). Here, CCL2 is linked to neoplasm.